Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Transcriptional Inhibitors Identified in a 160,000-Compound Small-Molecule DUX4 Viability Screen.

Journal of biomolecular screening - 1 Aug 2016

Choi Si Ho, Bosnakovski Darko, Strasser Jessica M, Toso Erik A, Walters Michael A, Kyba Michael

Abstract excerpt

Facioscapulohumeral muscular dystrophy is a genetically dominant, currently untreatable muscular dystrophy. It is caused by mutations that enable expression of the normally silent DUX4 gene, which encodes a pathogenic transcription factor. A screen based on Tet-on DUX4-induced mouse myoblast death previously uncovered compounds from a 44,000-compound library that protect against DUX4 toxicity. Many of those...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Gene Expression Regulation
Share to High-Throughput Screening Assays

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Homeodomain Proteins

Share to Muscular Dystrophy, Facioscapulohumeral

Share to Oxidative Stress

Share to Small Molecule Libraries

Share to Transcription, Genetic

Share to Transcriptional Activation

Source

Open in PubMed Open full text

Identifiers

PMID: 27245141
DOI: 10.1177/1087057116651868
PMCID: PMC5501317

Genes

DUX4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Transcriptional Inhibitors Identified in a 160,000-Compound Small-Molecule DUX4 Viability Screen.PMID 27245141Read ↗

A genome-wide CRISPR/Cas phenotypic screen for modulators of DUX4 cytotoxicity reveals screen complicationsSemantic proximity Read ↗

Influence of DUX4 Expression in Facioscapulohumeral Muscular Dystrophy and Possible TreatmentsSemantic proximity Read ↗

p53-independent DUX4 pathology in cell and animal models of facioscapulohumeral muscular dystrophy.Semantic proximity Read ↗

An isogenetic myoblast expression screen identifies DUX4-mediated FSHD-associated molecular pathologies.Semantic proximity Read ↗

Oligonucleotide Therapies for Facioscapulohumeral Muscular Dystrophy: Current Preclinical LandscapeSemantic proximity Read ↗

Therapeutic Approaches in Facioscapulohumeral Muscular Dystrophy.Semantic proximity Read ↗

Mitochondrial Respiratory Chain Function is crucial for Muscle Toxicity in Facioscapulohumeral Muscular DystrophySemantic proximity Read ↗

Vitamin B12 ameliorates the phenotype of a mouse model of DiGeorge syndrome.Semantic proximity Read ↗

Lessons Learned from Discontinued Clinical Developments in Duchenne Muscular DystrophySemantic proximity Read ↗

Clinically Advanced p38 Inhibitors Suppress DUX4 Expression in Cellular and Animal Models of Facioscapulohumeral Muscular DystrophySemantic proximity Read ↗

Myotonic dystrophy: candidate small molecule therapeuticsSemantic proximity Read ↗

Protein kinase A activation inhibits DUX4 gene expression in myotubes from patients with facioscapulohumeral muscular dystrophySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.